rs34997054

Variant summary

Our verdict is Benign. Variant got -13 ACMG points: 0P and 13B. BP4_StrongBP6BS1BS2

The NM_001130987.2(DYSF):​c.386G>A​(p.Gly129Glu) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00462 in 1,551,712 control chromosomes in the GnomAD database, including 98 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).

Frequency

Genomes: 𝑓 0.0041 ( 9 hom., cov: 33)
Exomes 𝑓: 0.0047 ( 89 hom. )

Consequence

DYSF
NM_001130987.2 missense

Scores

3
9
6

Clinical Significance

Conflicting classifications of pathogenicity criteria provided, conflicting classifications P:1B:17

Conservation

PhyloP100: 8.15
Variant links:
Genes affected
DYSF (HGNC:3097): (dysferlin) The protein encoded by this gene belongs to the ferlin family and is a skeletal muscle protein found associated with the sarcolemma. It is involved in muscle contraction and contains C2 domains that play a role in calcium-mediated membrane fusion events, suggesting that it may be involved in membrane regeneration and repair. In addition, the protein encoded by this gene binds caveolin-3, a skeletal muscle membrane protein which is important in the formation of caveolae. Specific mutations in this gene have been shown to cause autosomal recessive limb girdle muscular dystrophy type 2B (LGMD2B) as well as Miyoshi myopathy. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Aug 2008]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Benign. Variant got -13 ACMG points.

BP4
Computational evidence support a benign effect (MetaRNN=0.0076210797).
BP6
Variant 2-71511847-G-A is Benign according to our data. Variant chr2-71511847-G-A is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 94311.We mark this variant Likely_benign, oryginal submissions are: {Likely_benign=3, Likely_pathogenic=1, Benign=9}. Variant chr2-71511847-G-A is described in Lovd as [Likely_benign]. Variant chr2-71511847-G-A is described in Lovd as [Benign]. Variant chr2-71511847-G-A is described in Lovd as [Pathogenic]. Variant chr2-71511847-G-A is described in Lovd as [Pathogenic].
BS1
Variant frequency is greater than expected in population nfe. gnomad4 allele frequency = 0.00414 (631/152338) while in subpopulation NFE AF= 0.004 (272/68014). AF 95% confidence interval is 0.00361. There are 9 homozygotes in gnomad4. There are 312 alleles in male gnomad4 subpopulation. Median coverage is 33. This position pass quality control queck.
BS2
High Homozygotes in GnomAd4 at 9 AR gene

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
DYSFNM_001130987.2 linkc.386G>A p.Gly129Glu missense_variant Exon 5 of 56 ENST00000410020.8 NP_001124459.1 O75923-13
DYSFNM_003494.4 linkc.383G>A p.Gly128Glu missense_variant Exon 5 of 55 ENST00000258104.8 NP_003485.1 O75923-1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
DYSFENST00000410020.8 linkc.386G>A p.Gly129Glu missense_variant Exon 5 of 56 1 NM_001130987.2 ENSP00000386881.3 O75923-13
DYSFENST00000258104.8 linkc.383G>A p.Gly128Glu missense_variant Exon 5 of 55 1 NM_003494.4 ENSP00000258104.3 O75923-1

Frequencies

GnomAD3 genomes
AF:
0.00416
AC:
633
AN:
152220
Hom.:
10
Cov.:
33
show subpopulations
Gnomad AFR
AF:
0.00111
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00340
Gnomad ASJ
AF:
0.0597
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00331
Gnomad FIN
AF:
0.000941
Gnomad MID
AF:
0.0348
Gnomad NFE
AF:
0.00403
Gnomad OTH
AF:
0.00813
GnomAD3 exomes
AF:
0.00713
AC:
1118
AN:
156748
Hom.:
21
AF XY:
0.00750
AC XY:
619
AN XY:
82504
show subpopulations
Gnomad AFR exome
AF:
0.000571
Gnomad AMR exome
AF:
0.00529
Gnomad ASJ exome
AF:
0.0598
Gnomad EAS exome
AF:
0.00
Gnomad SAS exome
AF:
0.00474
Gnomad FIN exome
AF:
0.000965
Gnomad NFE exome
AF:
0.00491
Gnomad OTH exome
AF:
0.0115
GnomAD4 exome
AF:
0.00468
AC:
6545
AN:
1399374
Hom.:
89
Cov.:
31
AF XY:
0.00485
AC XY:
3348
AN XY:
690198
show subpopulations
Gnomad4 AFR exome
AF:
0.00212
Gnomad4 AMR exome
AF:
0.00521
Gnomad4 ASJ exome
AF:
0.0593
Gnomad4 EAS exome
AF:
0.0000839
Gnomad4 SAS exome
AF:
0.00413
Gnomad4 FIN exome
AF:
0.00108
Gnomad4 NFE exome
AF:
0.00346
Gnomad4 OTH exome
AF:
0.00805
GnomAD4 genome
AF:
0.00414
AC:
631
AN:
152338
Hom.:
9
Cov.:
33
AF XY:
0.00419
AC XY:
312
AN XY:
74494
show subpopulations
Gnomad4 AFR
AF:
0.00111
Gnomad4 AMR
AF:
0.00340
Gnomad4 ASJ
AF:
0.0597
Gnomad4 EAS
AF:
0.00
Gnomad4 SAS
AF:
0.00352
Gnomad4 FIN
AF:
0.000941
Gnomad4 NFE
AF:
0.00400
Gnomad4 OTH
AF:
0.00804
Alfa
AF:
0.00777
Hom.:
13
Bravo
AF:
0.00433
TwinsUK
AF:
0.00216
AC:
8
ALSPAC
AF:
0.00259
AC:
10
ESP6500AA
AF:
0.000508
AC:
2
ESP6500EA
AF:
0.00422
AC:
32
ExAC
AF:
0.00404
AC:
251
Asia WGS
AF:
0.00115
AC:
4
AN:
3478

ClinVar

Significance: Conflicting classifications of pathogenicity
Submissions summary: Pathogenic:1Benign:17
Revision: criteria provided, conflicting classifications
LINK: link

Submissions by phenotype

not specified Benign:5
Feb 22, 2022
Women's Health and Genetics/Laboratory Corporation of America, LabCorp
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

Variant summary: DYSF c.383G>A (p.Gly128Glu) results in a non-conservative amino acid change located in the Ferlin, first C2 domain (IPR037726) of the encoded protein sequence. Three of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.0071 in 156748 control chromosomes in the gnomAD database, including 21 homozygotes. The observed variant frequency is approximately 2-fold of the estimated maximal expected allele frequency for a pathogenic variant in DYSF causing Limb-Girdle Muscular Dystrophy, Autosomal Recessive phenotype (0.0031), strongly suggesting that the variant is benign. Eleven clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 and reported the variant with conflicting assessments (benign/likely benign [n=8], uncertain significance [n=2], likely pathogenic [n=1]). Based on the evidence outlined above, the variant was classified as benign. -

Mar 03, 2016
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

p.Gly129Glu in exon 5 of DYSF: This variant is not expected to have clinical sig nificance because it has been identified in 1.8% (162/8872) of European chromoso mes, including 3 homozygotes by the Exome Aggregation Consortium (ExAC, http://e xac.broadinstitute.org; dbSNP rs34997054). -

Sep 05, 2016
GeneDx
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. -

Jul 01, 2015
Eurofins Ntd Llc (ga)
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

-
Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen
Significance: Benign
Review Status: no assertion criteria provided
Collection Method: clinical testing

- -

Autosomal recessive limb-girdle muscular dystrophy type 2B Benign:4
May 28, 2019
Mendelics
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Sep 16, 2020
Natera, Inc.
Significance: Benign
Review Status: no assertion criteria provided
Collection Method: clinical testing

- -

Jan 02, 2020
Al Jalila Children’s Genomics Center, Al Jalila Childrens Speciality Hospital
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Sep 12, 2017
Counsyl
Significance: Likely benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

not provided Benign:3
-
Laboratory of Diagnostic Genome Analysis, Leiden University Medical Center (LUMC)
Significance: Likely benign
Review Status: no assertion criteria provided
Collection Method: clinical testing

- -

-
Genome Diagnostics Laboratory, University Medical Center Utrecht
Significance: Likely benign
Review Status: no assertion criteria provided
Collection Method: clinical testing

- -

Jan 01, 2025
CeGaT Center for Human Genetics Tuebingen
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

DYSF: BS1, BS2 -

Muscular dystrophy Pathogenic:1
Jun 18, 2017
Genomic Research Center, Shahid Beheshti University of Medical Sciences
Significance: Likely pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Autosomal recessive limb-girdle muscular dystrophy Benign:1
Feb 05, 2024
Molecular Genetics, Royal Melbourne Hospital
Significance: Likely benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Inborn genetic diseases Benign:1
Nov 14, 2013
Ambry Genetics
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

This alteration is classified as benign based on a combination of the following: population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -

DYSF-related disorder Benign:1
Dec 16, 2019
PreventionGenetics, part of Exact Sciences
Significance: Benign
Review Status: no assertion criteria provided
Collection Method: clinical testing

This variant is classified as benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). -

Miyoshi muscular dystrophy 1 Benign:1
May 18, 2021
Genome-Nilou Lab
Significance: Likely benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Qualitative or quantitative defects of dysferlin Benign:1
Jan 30, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.25
BayesDel_addAF
Benign
-0.053
T
BayesDel_noAF
Pathogenic
0.16
CADD
Uncertain
25
DANN
Uncertain
1.0
DEOGEN2
Benign
0.33
.;.;.;.;T;.;.;.;.;.;.
Eigen
Uncertain
0.63
Eigen_PC
Uncertain
0.60
FATHMM_MKL
Pathogenic
0.98
D
LIST_S2
Pathogenic
0.98
D;D;D;D;D;D;D;D;D;D;D
MetaRNN
Benign
0.0076
T;T;T;T;T;T;T;T;T;T;T
MetaSVM
Uncertain
-0.19
T
MutationAssessor
Benign
1.7
L;L;L;L;L;.;.;.;.;.;.
PrimateAI
Uncertain
0.60
T
PROVEAN
Uncertain
-2.7
D;D;D;D;D;D;D;D;D;D;D
REVEL
Uncertain
0.45
Sift
Uncertain
0.0020
D;D;D;D;D;D;D;D;D;D;D
Sift4G
Uncertain
0.025
D;D;D;D;D;D;D;D;D;D;D
Polyphen
1.0
D;D;D;D;D;D;D;D;D;D;D
Vest4
0.70
MVP
0.85
MPC
0.40
ClinPred
0.013
T
GERP RS
4.5
Varity_R
0.43
gMVP
0.42

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs34997054; hg19: chr2-71738977; COSMIC: COSV105093661; API